JP2024540863A - 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー - Google Patents

改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー Download PDF

Info

Publication number
JP2024540863A
JP2024540863A JP2024522065A JP2024522065A JP2024540863A JP 2024540863 A JP2024540863 A JP 2024540863A JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024540863 A JP2024540863 A JP 2024540863A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
taa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540863A5 (https=
Inventor
レイ ファン，
リウ ヤン，
シャン ガオ，
ウェンツー ゴン，
ユアンユアン ヤン，
Original Assignee
コンセプト トゥー メディシン バイオテック カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンセプト トゥー メディシン バイオテック カンパニー， リミテッド filed Critical コンセプト トゥー メディシン バイオテック カンパニー， リミテッド
Publication of JP2024540863A publication Critical patent/JP2024540863A/ja
Publication of JP2024540863A5 publication Critical patent/JP2024540863A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024522065A 2021-10-12 2022-10-12 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー Pending JP2024540863A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021123374 2021-10-12
CNPCT/CN2021/123374 2021-10-12
CN2022104995 2022-07-11
CNPCT/CN2022/104995 2022-07-11
PCT/CN2022/124961 WO2023061417A1 (en) 2021-10-12 2022-10-12 Cd3-targeting t-cell engagers with improved therapeutic index

Publications (2)

Publication Number Publication Date
JP2024540863A true JP2024540863A (ja) 2024-11-06
JP2024540863A5 JP2024540863A5 (https=) 2025-10-22

Family

ID=85987305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522065A Pending JP2024540863A (ja) 2021-10-12 2022-10-12 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー

Country Status (5)

Country Link
US (1) US20240417469A1 (https=)
EP (1) EP4415825A4 (https=)
JP (1) JP2024540863A (https=)
CN (1) CN118556083A (https=)
WO (1) WO2023061417A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202532431A (zh) * 2023-09-21 2025-08-16 大陸商樂普創一生物科技（上海）有限公司 多特異性抗體及其用途
WO2025103425A1 (en) * 2023-11-15 2025-05-22 Concept To Medicine Biotech Co., Ltd. Multispecific antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20260046525A (ko) * 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) * 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12509524B2 (en) * 2018-09-28 2025-12-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
CN113166261A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP2022504802A (ja) * 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers

Also Published As

Publication number Publication date
EP4415825A1 (en) 2024-08-21
EP4415825A4 (en) 2026-01-07
WO2023061417A1 (en) 2023-04-20
CN118556083A (zh) 2024-08-27
US20240417469A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
KR102224556B1 (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
JP7292200B2 (ja) 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP2025135612A (ja) 抗クローディン－１８．２と抗４－１ｂｂとの二重特異性抗体およびその使用
US20210206850A1 (en) Blocking antibodies against cd47 and methods of use thereof
KR20230146578A (ko) Bcma, gprc5d, 및 cd3을 표적화하는 삼중특이적 항체
JP2021524250A (ja) Ｐｓｍａ結合剤及びその使用
RS66901B1 (sr) Anti-cd3 antitela i njihova upotreba
JPWO2018147245A1 (ja) 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
US11497769B2 (en) Anti-CD19 antibodies
CN118994403B (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
WO2023061419A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
KR20240055080A (ko) Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
JP2023547530A (ja) 抗ｔｉｇｉｔ抗体およびその使用
KR20230028708A (ko) 항-b7-h4/항-4-1bb 이중특이적 항체 및 이의 용도
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
JP2017512772A (ja) Ｌｇ１〜３に特異的な抗ラミニン４抗体
JP2024540863A (ja) 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー
JP2023544140A (ja) 新規の抗クローディン１８抗体
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
HK40108102A (zh) 具有改善的治疗指数的靶向cd3的t细胞衔接器
HK40110049A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
TW202539744A (zh) 抗ｃｅａｃａｍ５抗體藥物軛合物
HK40113267A (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
JP2020054398A (ja) 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251014

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251119